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Simple Summary: Although renal tumors in children are mostly solid masses, cystic renal tumors
also occur. The most likely diagnoses for cystic renal tumors include cystic partially differentiated
nephroblastoma and cystic nephroma. Since these tumors are rare, limited information on the
treatment, clinical and molecular characteristics, and outcome is available. In this review, we aim
to summarize all reported patients with cystic partially differentiated nephroblastoma and cystic
nephroma. We identified 113 cystic partially differentiated nephroblastoma and 167 cystic nephroma
patients. Surgery was the cornerstone of treatment for both tumor types and chemotherapy was
generally not recommended. Cystic nephroma was often related to DICER1-mutations and second
tumors, whereas cystic partially differentiated nephroblastoma was related to somatic hyperdiploidy,
although testing was rare. The outcome for both tumors is favorable. This study provides information
for treatment decisions and stresses the importance of a central review of radiology and pathology,
as well as referral to a clinical geneticist.
Abstract: In children presenting with a predominantly cystic renal tumor, the most likely diagnoses
include cystic partially differentiated nephroblastoma (CPDN) and cystic nephroma (CN). Both
entities are rare and limited information on the clinical and molecular characteristics, treatment, and
outcome is available since large cohort studies are lacking. We performed an extensive literature
review, in which we identified 113 CPDN and 167 CN. The median age at presentation for CPDN
and CN was 12 months (range: 3 weeks–4 years) and 16 months (prenatal diagnosis–16 years),
respectively. No patients presented with metastatic disease. Bilateral disease occurred in both entities.
Surgery was the main treatment for both. Two/113 CPDN patients and 26/167 CN patients had
previous, concomitant, or subsequent other tumors. Unlike CPDN, CN was strongly associated with
somatic (n = 27/29) and germline (n = 12/12) DICER1-mutations. Four CPDN patients and one CN
patient relapsed. Death was reported in six/103 patients with CPDN and six/118 CN patients, none
directly due to disease. In conclusion, children with CPDN and CN are young, do not present with
metastases, and have an excellent outcome. Awareness of concomitant or subsequent tumors and
genetic testing is important. International registration of cystic renal tumor cohorts is required to
enable a better understanding of clinical and genetic characteristics.
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1. Introduction
Among children with renal tumors, cystic partially differentiated nephroblastoma
(CPDN) and cystic nephroma (CN) are rare diagnoses. CPDN and CN present as grossly
or entirely multicystic (multilocular) renal masses, while other pediatric renal tumors are
usually visible as solid masses on imaging studies, and 80–90% represent Wilms tumors
(nephroblastomas) [1].
Establishing the correct diagnosis requires careful histological examination of the
resected tumor, since imaging studies fail to discriminate between the two entities [2]. His-
tologically, CPDN is characterized by the presence of undifferentiated (blastemal) cells in
the septa of the cysts, and by the lack of solid components (tumor “nodules”). By definition,
CN does not contain any solid components or blastemal cells in the septa. Only mature
epithelial tubules, possibly from pre-existent normal renal tissue, are acceptable for the
diagnosis. Wilms tumors may contain cysts, particularly after pre-operative chemotherapy,
but the presence of solid tumor components or nodules excludes a diagnosis of CPDN or
CN [3]. CN has been found to be strongly associated with mutations in the DICER1 gene
(both germline and somatic) [4], which is not the case for CPDN, and whether there is a
biological relationship between the two entities remains to be clarified. Currently, treat-
ment recommendations are based on limited evidence, and a comprehensive overview of
the clinical characteristics, molecular aberrations, role of different treatment components,
and outcomes of CPDN and CN is not available. Here, we present the results of an exten-
sive literature review in which we aim to characterize the clinical and biological features
and outcome of CPDN and CN.
2. Methods
2.1. Literature Search
A complete search of the PubMed and EMBASE databases was performed to identify
all reports describing pediatric patients (age 0–18 years) with CPDN and/or CN published
until June 2020. We also included articles that described cystic Wilms tumors (cWT), as this
is the most important differential diagnosis in children with CPDN and CN. Synonyms
for CPDN, CN, and cWT were used as search terms (full search terms are presented in
Table S1). All manuscripts were screened by two independent reviewers (S.E.v.P. and
J.A.H.). To be eligible for inclusion, a study had to report well-described patients with
CPDN or CN aged 18 years or younger; had to be an original article; had to be written in
English, German, Spanish, or Dutch language; and had to be available as a full text. A cross
reference check was used to identify potential additional reports. In the case of multiple
case reports from the same authors or institution, we checked for previously reported
patients based on clinical descriptions and excluded duplicate cases if applicable. As cWT
is not a separate entity in the renal tumor histology classification by the International
Society of Pediatric Oncology Renal Tumor Study Group (SIOP-RTSG), we focused on
CPDN and CN in this review.
2.2. Classification of Tumors
Where necessary, tumors in this literature review were (re-)classified as CPDN or CN
by the authors and a pathology review member of the SIOP-RTSG based on pathology data
provided in the reports using the SIOP staging criteria for renal tumors of childhood [5].
This (re-)classification was performed for three reports, as two were published before
1989 [6,7], when the first diagnostic criteria by Joshi and Beckwith were established, or when
reports were not in agreement with the current definition of CPDN and CN (n = 1) [2],
which was revised in 2002 [5,8] (Table S2).
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3. Results
After the removal of duplicates, the literature search yielded 2009 articles, of which 110
were included after title/abstract and full-text screening (Figure 1). From these 110 reports,
a total of 280 patients were identified (167 patients with CN and 113 patients with CPDN)
(Table 1). Three additional CPDN cases were identified in our literature search, in which
detailed genetic characteristics of the tumor were investigated, but yielded no clinical
data [9–11]. These three cases are therefore not included in the description of clinical
characteristics; the molecular findings of these tumors are included in the table describing
the molecular characteristics of CPDN.
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Stage LN + Patients/Tested
Patients
Relapse Survival
I II III IV V NA
CPDN 113 73/38/2 12 (0.1–36) 484 (170–3110) 338 (122–405) 62 1 9 0 5 37 0/52 4 107
CN 167 93/72/2 16 (0–198) 540 (240–4000) 292 (6.7–1490) 51 0 1 0 9 106 0/24 1 161
M: male; F: female; NA: not available; LN: lymph nodes; +: positive.
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3.1. Cystic Partially Differentiated Nephroblastoma (CPDN)
3.1.1. Clinical Characteristics and Disease Stage
Of the 113 identified patients with CPDN (Table 1 and Table S3) with available clini-
cal data, 73 were male and 38 were female (sex was not specified in the remaining two).
The median age at diagnosis was 12 months (n = 106, range: 3 weeks–4 years). Clini-
cal presentation was described in detail in 44 patients (Table S4), with the most common
presentation being a palpable abdominal mass (n = 40/44). The median tumor weight at
surgery was 484 g (range 170–3110 g, n = 44) and the median described tumor volume was
338 mL (range 122–405 mL, n = 12).
A total of 108 patients presented with unilateral disease, while five presented with
bilateral disease (4.4%) [8,12–15], and none of the patients had metastatic disease. Three of
the bilateral cases had CPDN in both kidneys [12,14,15]. Of the other two patients, one had
CPDN with contralateral nephroblastomatosis [13] and one had CPDN with Wilms tumor,
with focal anaplasia in the other kidney [8]. The SIOP abdominal stage, according to the
SIOP staging criteria [16], could be identified in or assessed by the authors (based on the
information provided in the reports) for 72 patients. Stage I was recorded for 62 patients,
stage II for one patient with tumor extension beyond the kidney [12], and stage III for
nine patients. Stage III disease was based on invasion of the abdominal wall (n = 1) [17],
pre- or intra-operative tumor rupture (n = 7) [8,12,18,19], or not specified [14]. In six
patients, the tumor prolapsed into the ureter. Information on lymph node involvement
was documented for 52 patients and was negative in all cases.
3.1.2. Treatment and Outcome
Pre-operative chemotherapy administration was reported in 20 out of 98 patients with
reported details on the pre-operative therapy and response (Table 2) [12,14,15,17,19–24],
including two of the five patients with bilateral disease [12,14]. None of the pre-operatively
treated patients showed response to chemotherapy on imaging or histological examina-
tion. In three of them, pre-operative imaging revealed an increase in tumor size after
chemotherapy [14,15,23]. Seventy-eight patients underwent upfront surgery without
chemotherapy. Surgical resection (primary or after chemotherapy) of the tumor was per-
formed in 112/113 patients. The only patient who did not have surgery was a patient with
extensive comorbidity, where a conservative treatment approach was chosen, following
the parents’ wishes [25]. The surgical approach was radical nephrectomy in 94 cases and
nephron sparing surgery (NSS) in eight patients, with the latter including all five bilateral
patients [8,12–15]. The type of surgery was not described in 10 cases.





Pre-Op CT Pre-Op RT
Surgery Type Post-Op Treatment
TN NSS NA None CT RT CT + RT NA No Post-OpTherapy
CPDN 113 20 0 94 9 9 1 40 0 7 15 52
CN 167 9 5 121 28 16 2 5 0 0 110 52
CPDN: cystic partially differentiated nephroblastoma; CN: cystic nephroma; Pre-op: pre-operative; CT: chemotherapy; RT: radiotherapy;
TN: tumor nephrectomy; NSS: nephron-sparing surgery; NA: not available; post-op: post-operative.
Post-operative chemotherapy administration was reported in 47 patients. Fifty-two
patients did not receive any post-operative therapy based on the histological diagnosis
of CPDN, while information on post-operative therapy was not available in 14 patients.
Reported reasons for post-operative treatment (if specified) included tumor rupture or
spill (n = 7) [8,12,18,19], the presence of nephroblastomatosis (n = 1) [13], and the aim
to reduce serum α-fetoprotein levels, which occurred in one patient [21]. In the other
38/47 post-operatively treated patients, reasons for this decision were not specified. Pre-
operative chemotherapy strategies were vincristine, actinomycin-D, and doxorubicin in
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four patients; vincristine and actinomycin-D in one patient; actinomycin-D alone in one
patient; and not specified in 14 patients. Post-operative treatment strategies were vincristine
and actinomycin-D in 30 patients; vincristine alone in two patients; vincristine, actinomycin-
D, and doxorubicin in one patient; and not specified in 14 patients.
Only four case reports described detailed treatment-related toxicity occurring in a total
of seven patients [12,17,18,22]. Two of these seven patients suffered from vincristine-related
peripheral neuropathy [12], two developed intermittent viral illnesses and fevers [18,22],
and three developed hematologic toxicity, of which one had recurrent episodes of sep-
sis [12,17,22]. These toxicities resulted in dose reduction or a delay of chemotherapy in
these patients and one patient required supportive care therapy consisting of blood and
platelet infusions [17]. A total of four relapses were described (Table 3) [8,15,18]. In three
of these cases, a differential diagnosis of cystic Wilms tumor could not be excluded based
on the histological description in the original report, as most likely histology was not
reviewed by a panel of pediatric pathologists involved in the SIOP-RTSG or Children’s
Oncology Group (COG), and a detailed description was lacking. Molecular studies were
not performed for any of the patients that relapsed. A total of six deaths were described,
including two of the four relapsed cases, in whom cause of death was unrelated to CPDN
or unknown [15]. Two of the deaths included a patient with a concomitant stage III Wilms
tumor with focal anaplasia [8] and a patient with an underlying genetic syndrome (mosaic
variegated aneuploidy), which will be discussed below [25]. The last two patients with
CPDN who died were reported in a low income country and the cause of death was not
possible to retrieve [19]. We did not identify any relationship between the outcome and
chemotherapy treatment in these patients and large series of data that allow statistical
analysis are not available.
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Table 3. Clinical and treatment characteristics of relapsed patients.





1 CPDN [8] # 4m M None





incomplete None 1 y/2 y *** NA Surgery Yes
2 CPDN [18] # 1y M None
Pre- and intraoperative
cyst rupture, cystic tumor,
septa contained tissue
reminiscent of triphasic















3 CPDN bilateral [15] # 9m M None NA Bilateral NSS None 6 months Bilateral WT
Chemo,
surgery No *
4 CPDN [15] # 3y M Chemo NA
TN (positive
margins) Chemo 5 months NA Chemo No **





None 3 months NA NA Yes
CPDN: cystic partially differentiated nephroblastoma; #: these cases were previously reviewed by Kurian et al., 2018 [15]; preop Tx: pre-operative therapy; postop Tx: post-operative therapy; m: months;
y: years; TN: tumor nephrectomy; NSS: nephron sparing surgery; NA: not available; *: death unrelated to CPDN; **: lost to follow up, presumed death by authors; ***: two relapses, chemo: chemotherapy;
WT: Wilms tumor.
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3.1.3. Molecular Testing and Genetic Predisposition
Seven of the 113 CPDNs were tested for somatic DICER1 gene mutations, and all showed
negative results (Table 4). Eight CPDN tumors had been karyotyped, of which seven re-
vealed hyperdiploidy (varying from 50 to 52 chromosomes in tumor cells) [10,11,25,27–29].
In one case of CPDN, somatic loss of heterozygosity for 11p13, 11p15, and 16q was found
in the CPDN, as well as in the contralateral nephrogenic rest (all detected by PCR) [10]
(Table 4). WT1 mutation analysis was not performed for any of the CPDNs.
Genetic predisposition was reported in two cases. A 7-month-old female was diag-
nosed with Mulibrey Nanism caused by a germline TRIM37 mutation [30]. Another patient
was described with mosaic variegated aneuploidy characterized by premature centromere
divisions and mosaic hyperdiploidy in both tumor and healthy cells. This patient also
had a rhabdomyosarcoma and several congenital anomalies, which were both previously
described in patients with mosaic variegated aneuploidy [31]. No germline genetic testing
for the causative mutation was performed for this patient [25].
For the other patients, germline genetic testing of DICER1 or other genes was not
described, and they did not have additional tumors. One exception was the patient with
bilateral disease who had a Wilms tumor with focal anaplasia in the contralateral kidney
(no information on molecular or germline testing available). For the remaining four patients
with bilateral disease, germline testing was not described.
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Table 4. Molecular testing and genetic predisposition in tested patients with CPDN.
Reference No. of Tested Patients Karyotype
DICER1 Mutation Other molecular/Germline
AberrationsSomatic Germline
Charles et al. [10] 1 52, XY, +2, +5, +7, +8, +17, +18. LOH p13b, p15T, and 16q inCPDN and nephrogenic rest (somatic) NA NA -
Cummings et al. [9] 1 46XY, no LOH 11p13, 11p15, 16q, or 7p (somatic) NA NA -
De Chadarévian et al. [27] 1 51XY, +7, +8, +12, +13, +17, one cell disomic for chromosome 7(somatic) NA NA -
Doros et al. [32] 6 Not performed 0/6 0/6 -
Kaneko et al. [29] 2
Case no. 1 (74 in article):
50, XY, +6, +7 + 12, + 13, + 18/51, + 17
Case no. 2 (384 in article):
50, X, -Y, +6, +12, +13, +der(?)t(1;)(q21;?), +der(?)t(1;?)(q21;?)
(both somatic)
NA NA -
MdZin et al. [11] 1 Hyperdiploidy with presence of trisomy 12 (somatic) NA NA -
Stout et al. [14] 1 Not performed 0/1 0/1 -
Timmons et al. [28] 1
Clonal hyperdiploid karyotype, mostly: 51, XY, +8, + 12, +17, +
19, +20. trisomy 8 was present in every hyperdiploid examined.
Of the three hyperdiploid cells with 50 chromosomes, two
lacked the third copy of chromosome 17 and one lacked the
third copy of chromosome 12 (somatic)
NA NA -
Furukawa et al. [25] 1
Clonal hyperdiploid karyotype, mosaic trisomies occurring in
18 to 23% of somatic cells, in nephroblastoma cells mostly: 51,
XX, +2, +7, +8, +10, +12. Trisomy 11, 18, 19, and 20 and
monosomy 17 were also present in some aneuoploid cells
(somatic and germline)
NA NA Mosaic variegatedaneuploidy
Taskinen et al. [30] 1 Not performed NA NA Mulibrey Nanism (germlineTRIM37 mutation)
TOTAL 16 TOTAL 0 0
CPDN: cystic partially differentiated nephroblastoma; LOH: loss of heterozygosity; NA: not available.
Cancers 2021, 13, 997 10 of 18
3.2. Cystic Nephroma (CN)
3.2.1. Clinical Characteristics and Disease Stage
Of the 167 identified patients with CN (Table 1 and Table S5), 93 were male and 72
were female (for two patients, sex was not specified). The median age at diagnosis was
16 months (n = 113, range prenatal diagnosis—16 years). Similar to CPDN, a palpable
abdominal mass was, when documented, the most frequently reported presenting symp-
tom (62/88, 70%) (Table S4). The median reported tumor weight at surgery was 540 g
(range 120–4000 g, n = 60) and the median tumor volume was 292 mL (range 6.7–1490,
n = 37). Unilateral disease was reported in 158 patients and nine patients had bilateral CNs
(5.4%), including one patient with metachronous tumors [33]. None of the patients had
metastatic disease. The SIOP local stage was reported or assessed by the authors according
to the SIOP staging criteria [16] in 52 patients, of which 51 patients had stage I and one had
stage III disease based on intraoperative tumor rupture [3]. In three patients, the tumor
prolapsed into the ureter. Information on lymph node involvement was documented for
24 patients and none were positive for tumor cells.
3.2.2. Treatment and Outcome
Information on pre-operative chemotherapy administration was available for 142/167
patients (Table 2). Nine patients were treated with upfront chemotherapy [2,3,7,20,34–37].
The response was only reported in one chemotherapy-treated patient (with bilateral
CN) [32]. In the other eight chemotherapy-treated patients, the response was not described
on imaging or histological examination. Pre-operative radiotherapy was administered
in five patients, all in reports from before 1994 [7,20,37,38]. In three of these patients,
a pre-operative suspicion of a Wilms tumor was reported [7,37,38], for which pre-operative
radiotherapy was considered standard at that time (prior to 1980). In two other cases,
the treatment choice was not explained [20]. Surgery (upfront or after chemotherapy) was
performed in 165/167 patients.
The surgical approaches included radical nephrectomy in 121 cases and NSS in
28 cases, while the type of surgery was not available for 16 patients. Among the two
patients who did not have surgery, one patient had prenatally been diagnosed with CN
and polyhydramnios and this patient died before birth due to the premature rupture of
membranes at the gestational age of 16 weeks and six days [39]. The other patient had pre-
operatively been diagnosed with CN through a biopsy, leading to a conservative approach,
after which the tumor remained unchanged during a follow-up of eight months [35].
Post-operative chemotherapy administration was reported in five patients [40–44].
Details on response were not available for these post-operatively-treated patients. Fifty-two
patients did not receive post-operative chemotherapy and information on post-operative
therapy was not available for 110 patients. Reported reasons for chemotherapy treat-
ment after nephrectomy were concomitant pleuropulmonary blastoma (PPB) (n = 1) [40],
rapid pre-operative growth of the CN (n = 1) [41], suspicion of a Wilms tumor before obtain-
ing histology results (n = 1) [44], or not specified (n = 2) [42,43]. Pre-operative chemotherapy
strategies were vincristine and actinomycin-D in five patients; ifosfamide, carboplatin,
and etoposide in one patient; and not specified in three patients. Post-operative chemother-
apy strategies were vincristine and actinomycin-D in two patients; vincristine alone in
one patient; a combination of vincristine, doxorubicin, cyclophosphamide, iphosphamide,
carboplatin, and etoposide in one patient (PPB treatment); and not specified in one patient.
Three reports described treatment-related toxicity; two patients developed post-operative
sepsis (no chemotherapy) and died [38,45], and one patient suffered from chemotherapy-
related neutropenia [44].
One local relapse was described, most likely due to an incomplete resection of the
prior tumor (Table 3) [26]. Six patients died during follow up; in two cases related to CN
treatment (post-operative sepsis) [38,45], and in four cases due to complications caused by
treating concomitant disease including PPB (n = 2) [46,47] and brain hemorrhage during
surgery for cerebral spindle cell sarcoma (n = 1) [48]. In one patient, intrauterine death was
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reported [39]. We did not identify any relationship between the outcome and chemother-
apy treatment in these patients and large series of data that allow statistical analysis are
not available.
3.2.3. Molecular Testing and Genetic Predisposition
DICER1 mutations (germline and/or somatic) were identified in 33/35 tested cases
(Table 5). This included 12 patients with confirmed germline DICER1 mutations (or 14q32
deletion in one case); six of them also had a somatic DICER1 mutation in the tumor [48–53].
This was not assessed or described in the remaining five patients [54–56]. In 21 patients,
DICER1 mutations were identified in the tumor, but germline DNA was not analyzed.
Among them, 16 tumors harbored both a missense and truncating mutation, the latter of
which possibly represents germline events, as suggested by the study of Doros et al. [32].
Among 12 CN patients with germline DICER1 mutations, ten had previously or subse-
quently developed other tumors in addition to CN (Table 6). In the remaining 155 patients,
including nine patients with bilateral CN, germline genetic testing (DICER1 or other test-
ing) was not described. Prior to or following CN diagnosis, a total of 26 patients (for 17
of whom, the germline DICER1 status was not documented) developed DICER1-related
tumors (e.g., PPB, multinodular goiter, embryonal rhabdomyosarcoma, malignant teratoid
ciliary body medulloepithelioma, and others). Of the 26 CN patients that developed other
tumors, four developed these tumors before the CN, 14 were concomitant, and eight pa-
tients developed the other tumors after the CN. The time range between the tumors varied
from 1 month to 4 years. Two patients presented with a concomitant contra- or ipsilateral
Wilms tumor.
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Table 5. Somatic and germline aberrations in tested CN patients.
Reference No. of Tested Patients Karyotype (Tumor; Somatic)
DICER1-Mutation Positive
Tumor Germline
Saskin et al., 2017 [49] 1 Not performed c.5113G > A, p.E1705K Heterozygous c.4566_4570dupCTTTGp.V1524Afs * 38
Fernández-Martinez et al., 2017 [50] 1 Not performed c.5425G > A (p.G1809R) Heterozygous c.5387C > T; p.Q1783 *
De Kock et al., 2015 [51] 1 Not performed c.5439G > T p.(Glu1813Asp) Heterozygous c.1196_1197dupAGp.(Trp400Serfs * 59)
De Kock et al., 2018 [48] 1 Normal (46, XY) c.5425G > A, p.G1809R Heterozygous 5.82 Mb deletion at the14q32.13q32.2 region
Bardón-Cancho et al., 2017 [57] 1 Not performed Not tested Heterozygous c.3540C > G; p.Y1180
Cajaiba et al., 2016 [4] 16 Not performed
12 patients with LOF (nonsense or frameshift)
and hotspot mutations
3 patients with hotspot mutations only
Not tested *
Faure et al., 2016 [54] 2 Not performed Not tested Patient 1 LOF mutationPatient 2 mutation (NOS)
Li et al., 2017 [58] 7 Not performed
Patient 1. c.5125G > A; p.D1709N
Patient 2. c.5437G > A; pE1813K and
c.3452_3453delTG; p.V1151Efs12 *
Patient 3. c.5425G > A; G1809R
Patient 4. c. 5125G > A; p.D1709N and
c.958A>T; p.K320 *;
Patient 5. c.5428G > C; p.D1810H and c. 3091C
> T; p.Q1031 *
Patient 6: c.5125G > A; p.D1709N and c.1177C
> T; p.Q393 *
Not tested *
Bueno et al., 2017 [55] 2 Not performed Not tested Patient 1: Germline DICER1 variant (NOS)Patient 2: Germline DICER1 variant (NOS)
Wu et al., 2016 [52] 1 Not performed c.5438A > G; p.E1813G Heterozygous c.2450delC; p.P817LfsX15
Apellaniz-Ruiz et al., 2020 [53] 1 Not performed c.5428G > T, p.D1810Y c.4308_4311del, p.A1436fs
Dural et al., 2020 [56] 1 Not performed Not tested Heterozygous c.1525C>T p.Arg509 *
TOTAL 35 TOTAL 27 12
* These tumors harbored both a missense and a truncating DICER1 mutation. Germline DNA was not assessed, and the majority of truncating DICER1 mutations are suspected to be germline mutations;
NOS: not otherwise specified; LOF: loss-of-function.
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Table 6. Other tumors identified in patients with CN and CPDN.




CN (bilateral) [15] 4 Male ERMS urethra ### NA NA Yes
CN [49] 14 Female NBL *,## + + Yes
CN [50] 11 Female PPB ### + + Yes
CN (bilateral) [59] 30 Male PPB ## NA NA NA
CN (bilateral) [60] 9 Male PPB **,## NA NA Yes
CN [30] 18 Female PPB ## NA NA Yes
CN [46] 20 Male PPB ### NA NA No







CN [47] 54 Female PPB ### NA NA No









CN [61] 30 Male NBL ## NA NA Yes
CN [35] 22 Male PPB ## NA NA Yes
CN [40] 32 Male PPB ## NA NA Yes
CN [54] 66 Female SLCT # - + NA
CN [38] 24 Female WT ## NA NA Yes
CN [62] 5 Female PPB ## NA NA NA
CN [63] 11 Female PPB NA NA Yes
CN (bilateral) [63] 10 Female PPB ** NA NA Yes
CN [63] 26 Female PPB NA NA Yes
CN [55] 13 Male Pineal cyst - + NA





CN [36] 21 Female WT ## NA NA Yes
CN [52] 7 Female ASK ## + (in CN and ASK) + Yes
CN [53] 10 Male Paratesticular sarcoma ## + (in CN andparatesticular sarcoma) + Yes
CN [56] 12 Female ERMS uterus ### - + Yes





CPDN [8] 30 Female WT ## NA Yes
CPDN [25] 2 Female RMS # Multiple variegated aneuploidy No
CN: cystic nephroma; CPDN: cystic partially differentiated nephroblastoma; NA: not available; ERMS: embryonal rhabdomyosarcoma;
#: prior tumor; ##: concomitant tumor; ###: subsequent tumor; NBL: neuroblastoma; *: nodular hyperplasia of the thyroid; PPB: pleuropul-
monary blastoma; **: small bowel polyp; CBME: ciliary body medulloepithelioma; SCS: spindle cell sarcoma; SCLT: Sertoli-Leydig Cell
tumor; WT: Wilms tumor; ASK: anaplastic sarcoma of the kidney; RMS: rhabdomyosarcoma.
3.3. Differential Diagnosis of CN and CPDN
During our literature review, we encountered a broad range of other diseases that are
included in the differential diagnosis of cystic renal lesions. Reported non-malignant cystic
renal diseases included simple cysts, autosomal dominant or recessive polycystic kidney
disease, medullary cystic kidney disease, nephronophthisis, multicystic kidney disease,
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renal cysts and diabetes syndrome/HNF1B-associated renal disease and a medullary
sponge kidney. Malignant diseases included cystic subtypes of renal cell carcinoma and
cWT [64]. Since cWT, CPDN, and CN were often proposed to be part of a spectrum,
we included cWT in our literature search. We identified 18 cases of cWT, many of which
were reported > 20 years ago, which are summarized in Table S6. The median age was
10 months (individual ages available from 14 patients) and presenting symptoms were most
frequently an abdominal mass and, more rarely, fever or malaise. Two patients presented
with metastatic disease. Except for two patients (siblings) with an unspecified underlying
syndrome, all patients were successfully treated with surgery and chemotherapy, or surgery
alone. In this review, we focused on CPDN and CN, as cWT is not a separate entity in the
SIOP-RTSG classification, and after our search, we noticed that cWT reports, apart from
being > 20 years old, were scarce.
4. Discussion
This literature review, in which we identified 113 patients with CPDN and 167 patients
with CN, demonstrated that CPDN and CN are clinically difficult to distinguish from each
other. Both tumors are characterized by a similar younger age at diagnosis (median age of
12 and 16 months, respectively) than other renal tumors, such as a Wilms tumor (median
three years) or renal cell carcinoma (adults and adolescents) [65]. Most patients present
with a palpable or visible abdominal mass, similar to what is observed in patients with
Wilms tumors. Both CPDN and CN are apparently associated with the absence of lymph
node involvement or metastatic disease. They have a very low relapse rate and an excel-
lent outcome. Nevertheless, second primary (malignant) tumors can occur, particularly
in patients with CN and underlying DICER1 syndrome, which illustrates the need for
awareness and surveillance of these children, even though surgery is the most important
treatment modality and response to chemotherapy seems to be limited.
It is challenging to correctly diagnose CPDN or CN based on clinical characteristics or
radiology. Imaging studies do not seem to be able to reliably discriminate CN from
CPDN or other cystic (Wilms) tumors, although Bosniak classification might help to
distinguish these entities from other cystic kidney diseases, such as polycystic kidneys,
by the stratification of renal cysts into different subcategories based on imaging features [64].
Biopsies to confirm the diagnosis are not encouraged, as cystic tumors carry a high risk
of tumor spillage and the biopsied region may not be representative of the tumor [16].
In children with an entirely cystic (unilateral) tumor on imaging studies, immediate surgery
is recommended in most renal tumor protocols, including the recently launched SIOP-RTSG
UMBRELLA protocol, albeit after a review by a pediatric radiologist with specific expertise
in this field [3]. It is crucial to exclude benign forms of cystic kidney disease as unilateral
nephrectomy may accelerate the course of disease in these cases [66]. Chemotherapy and
radiotherapy are generally not recommended for CN or CPDN. Nevertheless, we found
that pre- and/or post-operative chemotherapy was sometimes administered in the past
to patients with CPDN and occasionally to patients with CN. A response to preoperative
chemotherapy has not been observed, except for one case of bilateral rapidly growing
CN, in which pre-operative chemotherapy administration led to growth arrest, averting
end-stage renal disease [32]. Large cohort studies comparing outcomes with and without
chemotherapy are not available. It remains questionable whether there is a role for post-
operative chemo- and radiotherapy in the case of tumor rupture when tumor spillage may
have occurred.
Bilateral disease occurs in both CN (5.3% of patients) and CPDN (4.4% of patients),
suggesting a genetic predisposition, or a shared precursor lesion early in kidney devel-
opment, in these patients. For CN, the occurrence of bilateral tumors is likely largely
explained by underlying germline DICER1 mutations, although only 12/167 reported
patients with CN were tested for DICER1 syndrome. For CPDN, only two patients were
reported to have a genetic predisposition, but the majority were not referred for assessment
by a clinical geneticist and/or genetic testing and genetic predisposition syndromes may
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have been missed. Therefore, referral to a clinical geneticist is important for all patients
with CN, who should be evaluated for DICER1 syndrome so that they can receive adequate
follow-up, and for patients with CPDN, where genetic testing can be considered based on
the presence of bilateral disease, family history, and/or additional phenotypic features.
Both CN and CPDN have been reported to occur in combination with contralateral
Wilms tumor. Since the clinical and radiological features of both entities are similar, previ-
ous studies have suggested that solid Wilms tumors, CPDN, and CN represent a spectrum
of differentiation, with solid Wilms tumors being the least differentiated and CN being
the most differentiated end of the spectrum [8]. Alternatively, it has been suggested that
CN, CPDN, and Wilms tumors may share a common origin in intralobar nephrogenic
rests [36]. The high frequency of DICER1 mutations in CN and the absence of DICER1
mutations in CPDN have led Cajaiba et al. to classify CN as a separate entity, rather than
as part of a spectrum together with CPDN [4]. It is intriguing that DICER1 mutations (both
germline and somatic) have also been identified in solid Wilms tumor cases [67] and the
co-occurrence of CN and a Wilms tumor has been reported twice [36,38]. Somatic DICER1
mutations have never been identified in CPDN, for which molecular testing has only
been sporadically reported [14,32]. Somatic hyperdiploidy appeared to be common in
CPDNs of nonsyndromic patients (seven of eight karyotyped cases). Hyperdiploidy has
previously also been associated with Wilms tumors, in which the level of hyperdiploidy
shows a correlation with the histological subtype [68]. We did not identify any reports
describing hyperdiploidy in CN, where karyotyping was only rarely performed. In the
future, standardized broad genomic screening may identify aberrations that help to dis-
criminate between cWT, CN, and CPDN, which may even be feasible before surgery by
using circulating cell-free DNA techniques [69].
Although CN and CPDN are both considered relatively benign or low-risk lesions,
relapses were occasionally reported. In CPDN, four relapses were reported, but the initial
histological diagnosis was not always entirely clear in the original report, and we hypoth-
esize that, in some of these cases, solid components may have been present in the cyst
walls, suggesting an initial diagnosis of cWT rather than CPDN [8,15,18]. In CN, one local
relapse was reported, which was attributed to incomplete resection by the authors of the
original report [26]. Deaths in this literature review were due to the toxicity of chemother-
apy or comorbidity in both CPDN and CN, rather than disease progression. Notably,
the malignant transformation of CN to anaplastic sarcoma [52] or anaplastic malignant
mesenchymoma [44] has been reported. A limitation of our review is that the follow-up
time was frequently not reported or highly variable between different reports.
5. Conclusions
This review summarizes the clinical and molecular characteristics and outcome of all
reported CN and CPDN in children. It emphasizes that CN and CPDN are difficult to dis-
tinguish based on patient characteristics, presenting symptoms, and radiology. They have
an overall favorable outcome and the benefit of chemotherapy seems to be limited. Aware-
ness of concomitant tumors in the kidneys, lungs, and other organs is important, especially
in CN patients, and genetic testing and counselling is advised, as well as a central re-
view of histology and radiology, in order to avoid unnecessary treatment and to identify
other tumors at an early stage. In the future, genomic sequencing studies (germline and
somatic) and the prospective registration of genetic, clinical, and tumor characteristics
will likely provide more insight into the biological relationships between CN, CPDN,
and Wilms tumor subtypes. International collaboration is needed to prospectively register
large cohorts. The SIOP 2016 UMBRELLA protocol, which aims to capture all renal tumors
prospectively with enhanced characterization of phenotype and genomic sequencing, and
a central review of histology and radiology of the tumors, may identify further unique and
discriminating features in the future.
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